Nasal cavity administrated prepn for treating cerebral tumor

Abstract

The present invention relates to one kind of nasal cavity administrated preparation of methotrexate to target to brain. The present invention is suitable for preventing and treating primary and metastatic cerebral tumor, meningeal leukaemia, cerebral infiltration of leukaemia, etc. The preparation contains methotrexate or its medicinal acceptable salt as well as pharmacological acceptable supplementary material. After being administrated, the medicine reaches brain fast and is enriched in brain to produce high disease preventing and treating effect while the medicine density in blood and other tissues is reduced to decrease general side effect, the preparation has also the advantages of fast release and less nasal cilium toxicity.

Description

technical field [0001] The invention belongs to the field of chemical pharmacy, and in particular relates to a preparation for targeting the antitumor drug methotrexate to the brain through the nasal cavity administration route. Background technique [0002] Malignant tumor is one of the serious diseases that endanger human health and cause death. According to reports, 5.9 million people worldwide develop tumors every year, and 4.3 million people die from them. The incidence of cancer in my country is about 105 / 100,000, and there are about 1.25 million new patients every year, and about 900,000 people die from the disease. [0003] Brain tumors are divided into benign and malignant, primary and metastatic. Among the primary brain tumors, glioma is the most common, accounting for more than 40%, while the brain infiltration of leukemia accounts for more than 50% of children's brain tumors; brain tumors can occur at any age, around 10 years old and 30-40 years old There are ...

AI Technical Summary

Problems solved by technology

Because methotrexate is not easy to pass through the blood-brain barrier, it limits its treatment of malignant brain tumors, brain invasion of leukemia, etc.